Completed PHASE2 INTERVENTIONAL 2-arm NCT01037517

Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization

Open Label Phase II Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization

Sponsor: CancerCare Manitoba

Conditions Lymphoma Multiple Myeloma

Interventions Observation: Nonintervention Plerixafor

Updated 5 times since 2017 Last updated: Oct 30, 2013 Started: Jan 31, 2010 Primary completion: Aug 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lymphoma and Multiple Myeloma and is currently completed. CancerCare Manitoba leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CancerCare Manitoba

Data source: CancerCare Manitoba

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winnipeg, Canada